New York, USA, Dec. 01, 2025 (GLOBE NEWSWIRE) — Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025\u20132034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight<\/b><\/p>\n
The dynamics of the geographic atrophy market are expected to change in the coming years due to the rising global prevalence driven by aging populations, demand for disease-modifying interventions, and the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), Tinlarebant (Belite Bio), AVD-104 (Aviceda Therapeutics), JNJ-1887 (Johnson & Johnson Innovative Medicine), OGX-110 (Ocugenix), OCU410 (Ocugen), BI 1584862 (Boehringer Ingelheim), and others.<\/i><\/b><\/p>\n
DelveInsight\u2019s Geographic Atrophy Market Insights<\/b><\/a> report includes a comprehensive understanding of current treatment practices, emerging geographic atrophy drugs, market share of individual therapies, and current and forecasted geographic atrophy market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).<\/p>\n Geographic Atrophy Market Summary<\/b><\/p>\n Discover which geographic atrophy medications are expected to grab the market share @ Geographic Atrophy Market Report<\/b><\/a><\/p>\n Key Factors Driving the Growth of the Geographic Atrophy Market\u00a0<\/b><\/a><\/p>\n Rising Geographic Atrophy Prevalence<\/b><\/p>\n The prevalence of geographic atrophy, an advanced form of age-related macular degeneration, is steadily rising due to global population ageing and increased life expectancy. As more individuals enter older age groups, the number of those at risk for geographic atrophy has grown significantly.\u00a0<\/p>\n Emerging Diagnostic Technologies in Geographic Atrophy<\/b><\/p>\n New diagnostic technologies, such as spectral-domain OCT and fundus autofluorescence, have emerged, giving ophthalmologists a clearer picture of the eye and aiding the confirmation of anatomic endpoints for geographic atrophy.<\/p>\n ANX007 Milestone in Geographic Atrophy<\/b><\/p>\n ANX007 is the first therapeutic candidate for the treatment of geographic atrophy to receive PRIME designation in the EU, which provides early and proactive support to developers of promising medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options.<\/p>\n Evidence Supporting RPE Cell Therapy for Geographic Atrophy<\/b><\/p>\n Data from both CPCB-RPE1 and OpRegen provide a very strong likelihood that RPE cells are an effective means of treating geographic atrophy.<\/p>\n Launch of Emerging Geographic Atrophy Drugs<\/b><\/p>\n The launch of geographic atrophy drugs such as Gildeuretinol <\/b>(Alkeus Pharmaceuticals), Tinlarebant <\/b>(Belite Bio), AVD-104<\/b> (Aviceda Therapeutics), JNJ-1887<\/b> (Johnson & Johnson Innovative Medicine), OGX-110<\/b> (Ocugenix), OCU410 <\/b>(Ocugen), BI 1584862<\/b> (Boehringer Ingelheim), JNJ-1887 sCD59 <\/b>(Janssen Research & Development, LLC), OpRegen <\/b>(Lineage Cell Therapeutics (CellCure Neurosciences) and Roche), CT1812<\/b> (Cognition Therapeutics), Elamipretide <\/b>(Stealth BioTherapeutics), EG-301<\/b> (Evergreen Therapeutics), ANX007 <\/b>(Annexon Biosciences), NGM621 <\/b>(NGM Biopharmaceuticals), Danicopan<\/b> (ALXN2040) <\/b>(AstraZeneca\/Alexion Pharmaceuticals), IONIS-FB-LRx<\/b> (Ionis Pharmaceuticals\/Roche), CPCB-RPE1<\/b> (Regenerative Patch Technologies), and others are expected to change the dynamics of the geographic atrophy market in the coming years.<\/p>\n Geographic Atrophy Market Analysis<\/b><\/p>\n Agents that modulate the immune response have become the most advanced segment within clinical research for geographic atrophy, marking a major milestone as the first and only class of therapies to reach the market so far. The FDA approvals of IZERVAY <\/b>(avacincaptad pegol) and SYFOVRE <\/b>(pegcetacoplan) represent significant breakthroughs in this space.<\/p>\n While IZERVAY and SYFOVRE offer new hope for individuals with late-stage AMD, they also represent only the beginning of therapeutic progress for geographic atrophy. Safety-related setbacks temporarily slowed SYFOVRE\u2019s early momentum and dampened its initial market lead. Nevertheless, Apellis reported strong Q4 sales, demonstrating robust growth for SYFOVRE. Looking ahead, with several new therapies expected to seek regulatory approval between 2025 and 2027, the evolution of the geographic atrophy treatment landscape will be worth watching. For now, SYFOVRE and IZERVAY face no immediate competitive threats, as no other products are nearing approval.<\/p>\n Surgical approaches for geographic atrophy management include the PRIMA Bionic Vision System, the SING-IMT implant, and the OcuDyne neuro-interventional procedure. A wide range of therapies is currently in development to slow disease progression and preserve macular function in dry AMD. Among the promising candidates under investigation are ALK-001, Tinlarebant, Elamipretide, and OGX-110<\/b>. Many of these aim to prevent disease onset or halt worsening.<\/p>\n Given the older demographic affected by geographic atrophy, treatments with every-other-month dosing may see higher demand. As a result, options offering monthly dosing, or even a one-time administration, could capture meaningful market share. With a large patient population and considerable unmet need, future therapies have significant potential to become the standard of care.<\/p>\n Learn more about the geographic atrophy treatment options @ Geographic Atrophy Treatment Market<\/b><\/a><\/p>\n Geographic Atrophy Competitive Landscape<\/b><\/p>\n Some of the geographic atrophy drugs in clinical trials include Gildeuretinol <\/b>(Alkeus Pharmaceuticals), Tinlarebant <\/b>(Belite Bio), AVD-104<\/b> (Aviceda Therapeutics), JNJ-1887<\/b> (Johnson & Johnson Innovative Medicine), OGX-110<\/b> (Ocugenix), OCU410 <\/b>(Ocugen), BI 1584862<\/b> (Boehringer Ingelheim), JNJ-1887 sCD59 <\/b>(Janssen Research & Development, LLC), OpRegen <\/b>(Lineage Cell Therapeutics (CellCure Neurosciences) and Roche), CT1812<\/b> (Cognition Therapeutics), Elamipretide <\/b>(Stealth BioTherapeutics), EG-301<\/b> (Evergreen Therapeutics), ANX007 <\/b>(Annexon Biosciences), NGM621 <\/b>(NGM Biopharmaceuticals), Danicopan<\/b> (ALXN2040) <\/b>(AstraZeneca\/Alexion Pharmaceuticals), IONIS-FB-LRx<\/b> (Ionis Pharmaceuticals\/Roche), CPCB-RPE1<\/b> (Regenerative Patch Technologies), and others.<\/p>\n Alkeus Pharmaceuticals\u2019 Gildeuretinol (ALK-001)<\/b> is an oral, once-daily investigational therapy for geographic atrophy. It is a chemically modified form of vitamin A designed to limit the buildup of toxic by-products that contribute to retinal degeneration. In addition to geographic atrophy, ALK-001 is also being tested for potential use in Stargardt disease.<\/p>\n Belite Bio\u2019s Tinlarebant<\/b> is an innovative oral drug designed to reduce harmful by-products of the visual cycle that drive STGD1 and contribute to geographic atrophy, an advanced form of dry AMD. A global, two-year Phase III trial (PHOENIX) is currently underway. This randomized, double-masked, placebo-controlled study is assessing Tinlarebant\u2019s safety and effectiveness in patients with geographic atrophy. In November 2023, Belite Bio received MHRA approval in the UK to proceed with this Phase III study. The company plans an interim analysis at the midpoint of the trial.<\/p>\n Ocugenix\u2019s OGX-110<\/b>, formerly known as Ocu-110, is a small-molecule therapy that precisely targets the CXCR3 signaling pathway\u2014an essential regulator of tissue repair that helps remove abnormal blood vessels, limit fibrosis, and restore the balance of wound healing. By binding to the natural CXCR3 receptor site, OGX-110 promotes a regenerative healing response, counteracting pro-angiogenic and pro-fibrotic factors such as VEGF. The therapy is currently in Phase I clinical testing.<\/p>\n The anticipated launch of these emerging geographic atrophy therapies are poised to transform the geographic atrophy market landscape in the coming years. As these cutting-edge geographic atrophy therapies continue to mature and gain regulatory approval, they are expected to reshape the geographic atrophy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n To know more about new treatment for geographic atrophy, visit @ Geographic Atrophy Medication<\/b><\/a><\/p>\n Recent Developments in the Geographic Atrophy Market<\/b><\/p>\n What is Geographic Atrophy?<\/b><\/p>\n Geographic atrophy is an advanced form of age-related macular degeneration (AMD), a progressive eye disease that affects the retina, the light-sensitive tissue at the back of the eye. In geographic atrophy, areas of retinal cells, including the photoreceptors, retinal pigment epithelium (RPE), and underlying choriocapillaris, gradually degenerate, creating well-defined patches of vision loss. These areas expand over time, leading to difficulties with tasks such as reading, recognizing faces, and seeing in low light. Although geographic atrophy does not typically cause complete blindness, it can severely impair central vision and quality of life. Currently, geographic atrophy remains a chronic, irreversible condition, but emerging therapies aim to slow its progression.<\/p>\n Geographic Atrophy Epidemiology Segmentation<\/b><\/p>\n The geographic atrophy epidemiology section provides insights into the historical and current geographic atrophy patient pool and forecasted trends for the leading markets. In geographic atrophy cases, moderate-to-severe visual impairment is predominant, accounting for more than 40%<\/b>, while occurrences requiring surgery or leading to legal blindness are less common.<\/p>\n The geographic atrophy market report<\/b><\/a> proffers epidemiological analysis for the study period 2020\u20132034 in the leading markets segmented into:<\/p>\n Download the report to understand geographic atrophy management @ Geographic Atrophy Treatment Options<\/b><\/a><\/p>\n\n
\n
![](\"https:\/\/ml.globenewswire.com\/Resource\/Download\/748e97ef-1190-4ff6-a8d3-78959fd3c4f6\/geographic-atrophy-market.jpg\" "\\"Geographic-Atrophy-Market.jpg\\"")
<\/b><\/p>\n\n
\n
![\"\"](\"https:\/\/ml.globenewswire.com\/media\/ZTI2MzFhMTctMGUwNy00ZDZiLWIzMTUtNzI1MzEzY2NiODg3LTEyMDQ5MzgtMjAyNS0xMi0wMS1lbg==\/tiny\/DelveInsight-Business-Research.png\")
\n <\/div>\n","protected":false},"excerpt":{"rendered":"